EPO and diabetic kidney disease: Two of these candidate genes are targets for drugs currently used to treat diabetic complications (VEGF for DR and ACE for DKD); three of these candidate genes have additional evidence supporting them as possible drug targets (ACACB, TCF7L2, and EPO).